Table 3.

Factors associated with severe or recurrent bacterial infections in logistic regression models

OR95% CIP
Univariate analysis    
 AIC at splenectomy (ES)* 1.31 0.34-5.34 .70 
 AIC at splenectomy (cITP)* 0.17 0.05-0.65 .007 
 Sex 0.58 0.21-1.54 .29 
 Age at first AIC 0.87 0.75-0.98 .029 
 Rituximab before splenectomy 0.73 0.16-2.38 .64 
 Number of treatments before splenectomy 0.98 0.64-1.36 .93 
 Time from first AIC to splenectomy 0.99 0.83-1.15 .91 
 Age at splenectomy 0.87 0.82-0.93 .021 
 IM diagnosed before splenectomy 7.11 2.61-20.30 .0002 
 IM at any timepoint during follow-up 10.64 3.60-39.20 6.9 × 10−5 
 New second-line treatment after splenectomy† 12.7 3.98-56.7 .0001 
 Number of second-line treatment† 0.99 0.77-1.19 .90 
Multivariate analysis, model with IM diagnosed before splenectomy    
 AIC at splenectomy (ES)* 0.47 0.07-2.83 .42 
 AIC at splenectomy (cITP)* 0.27 0.06-1.26 .088 
 Age at first AIC 1.00 0.80-1.26 1.00 
 Age at splenectomy 0.93 0.75-1.13 .49 
 IM diagnosed before splenectomy 3.96 1.001-17.23 .049 
 New second-line treatment after splenectomy† 7.19 2.00-34.1 .0048 
Multivariate analysis, model with IM diagnosed at any timepoint during follow-up    
 AIC at splenectomy (ES)* 0.67 0.13-3.41 .63 
 AIC at splenectomy (cITP)* 0.34 0.08-1.53 .15 
 Age at first AIC 0.99 0.79-1.25 .91 
 Age at splenectomy 0.89 0.72-1.09 .29 
 IM at any timepoint during follow-up 5.43 1.31-26.89 .026 
 New second-line treatment after splenectomy† 4.73 1.19-24.00 .037 
OR95% CIP
Univariate analysis    
 AIC at splenectomy (ES)* 1.31 0.34-5.34 .70 
 AIC at splenectomy (cITP)* 0.17 0.05-0.65 .007 
 Sex 0.58 0.21-1.54 .29 
 Age at first AIC 0.87 0.75-0.98 .029 
 Rituximab before splenectomy 0.73 0.16-2.38 .64 
 Number of treatments before splenectomy 0.98 0.64-1.36 .93 
 Time from first AIC to splenectomy 0.99 0.83-1.15 .91 
 Age at splenectomy 0.87 0.82-0.93 .021 
 IM diagnosed before splenectomy 7.11 2.61-20.30 .0002 
 IM at any timepoint during follow-up 10.64 3.60-39.20 6.9 × 10−5 
 New second-line treatment after splenectomy† 12.7 3.98-56.7 .0001 
 Number of second-line treatment† 0.99 0.77-1.19 .90 
Multivariate analysis, model with IM diagnosed before splenectomy    
 AIC at splenectomy (ES)* 0.47 0.07-2.83 .42 
 AIC at splenectomy (cITP)* 0.27 0.06-1.26 .088 
 Age at first AIC 1.00 0.80-1.26 1.00 
 Age at splenectomy 0.93 0.75-1.13 .49 
 IM diagnosed before splenectomy 3.96 1.001-17.23 .049 
 New second-line treatment after splenectomy† 7.19 2.00-34.1 .0048 
Multivariate analysis, model with IM diagnosed at any timepoint during follow-up    
 AIC at splenectomy (ES)* 0.67 0.13-3.41 .63 
 AIC at splenectomy (cITP)* 0.34 0.08-1.53 .15 
 Age at first AIC 0.99 0.79-1.25 .91 
 Age at splenectomy 0.89 0.72-1.09 .29 
 IM at any timepoint during follow-up 5.43 1.31-26.89 .026 
 New second-line treatment after splenectomy† 4.73 1.19-24.00 .037 

Boldfaced numbers are statistically significant associations.

OR, odds ratio.

*

Autoimmune hemolytic anemia used as the reference group for this categorical variable.

†

Only second-line treatments initiated before severe or recurrent infection were considered.

View Large
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal